Johnson & Johnson's TREMFYA shows efficacy in perianal fistulizing Crohn's
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
May 5, 2026 8:05 AM EDTTREMFYA® demonstrated significantly higher rates of combined fistula remission complete external closure of draining fistulas and absence of fluid collection on MRI compared to placebo at Week 24
First study of its kind in 20 years for this debilitating manifestation of Crohn's disease presented as late-breaking data at Digestive Disease Week 2026
CHICAGO, May 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:Â JNJ) today announced results from the Phase 3... More
